Pear Therapeutics launches Somryst for chronic insomnia

Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
reSET-O dashboard

Pear Therapeutics publishes real-world utilization data for reSET-O

Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
Pear Therapeutics reSET and reSET-O

PreferredOne taps Pear to become the first health plan to cover digital therapeutics

PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.

Sandoz, Pear Therapeutics launch reSET to treat SUD patients

Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone.
PEAR Therapeutics reSET

Magellan Health to pilot PEAR Therapeutics’ digital therapeutic reSET

The pilot program will enroll 250 patients with Substance Use Disorders (SUD) and offer each patient a 12-week course of reSET therapy.
Pear Therapeutics

Pear Therapeutics gets $20M for its prescription digital therapies

The company will use the money to build and launch a portfolio of eFormulations, including reSET and reSET-O, for treating substance use disorder.
Corey McCann MD, PhD

Interview with Pear Therapeutics’ founder and CEO – Corey McCann MD, PhD

The company has offices in Boston and San Francisco, and is developing drug/software combination products to address a broad range of severe conditions.

Pear Therapeutics raises money from 5AM Ventures

The company makes prescription pharmaceutical-software combination products called eFormulations, which enhance the efficacy of pharmaceutical preparations.